Basit öğe kaydını göster

dc.contributor.authorLeblebicioglu, Hakan
dc.contributor.authorCakir, Nedim
dc.contributor.authorCelen, Mustafa
dc.contributor.authorKurt, Halil
dc.contributor.authorBaris, Hakan
dc.contributor.authorLaeuffer, Joerg
dc.date.accessioned2020-06-21T14:28:03Z
dc.date.available2020-06-21T14:28:03Z
dc.date.issued2012
dc.identifier.issn1471-2334
dc.identifier.urihttps://doi.org/10.1186/1471-2334-12-42
dc.identifier.urihttps://hdl.handle.net/20.500.12712/16644
dc.descriptionLeblebicioglu, Hakan/0000-0002-6033-8543;en_US
dc.descriptionWOS: 000301448400001en_US
dc.descriptionPubMed: 22340940en_US
dc.description.abstractBackground: Recent evidence indicates that Gram-negative bacterial pathogens, the most common of which are Pseudomonas spp., Enterobacteriaceae, and Acinetobacter baumannii, are frequent causes of hospital-acquired infections. This study aims to evaluate the in vitro activity of doripenem and comparator carbapenem antibiotics against Gram-negative clinical isolates collected from COMParative Activity of Carbapenem Testing (COMPACT) study centres in Turkey. Methods: Ten centres in Turkey were invited to submit Pseudomonas aeruginosa, Enterobacteriaceae, and other Gram-negative isolates from intensive care unit (ICU)/non-ICU patients with complicated intra-abdominal infections, bloodstream infections, or nosocomial pneumonia, including ventilator-associated pneumonia, between May and October 2008. Susceptibility was determined by each centre using E-test. A central laboratory performed species confirmation as well as limited susceptibility and quality-control testing. Results: Five hundred and ninety six isolates were collected. MIC90 values for doripenem, meropenem, and imipenem, respectively, were 32, >= 64, and >= 64 mg/L against Pseudomonas spp.; 0.12, 0.12, and 0.5 mg/L against Enterobacteriaceae; and >= 64 mg/L for each against other Gram-negative isolates. In determining the susceptibility of hospital isolates of selected Gram-negative pathogens to doripenem, imipenem, and meropenem, we found that against all pathogens combined, the MIC90 for ICU compared with non-ICU isolates was higher. Conclusions: Doripenem showed similar or slightly better activity than meropenem and better activity than imipenem against the Gram-negative pathogens collected in Turkey.en_US
dc.description.sponsorshipJanssen EMEAen_US
dc.description.sponsorshipThis work was supported by Janssen EMEA. The decision to submit this article for publication was made by Janssen and the authors. No financial support or honorarium was given to the non-Janssen authors for the development of this manuscript. H. Baris and J. Laeuffer are employees of Janssen EMEA. These authors were not awarded any additional support outside of their salaries for their participation in this study. Editorial assistance was provided by Phase Five Communications Inc., which was funded by Janssen EMEA.en_US
dc.language.isoengen_US
dc.publisherBiomed Central Ltden_US
dc.relation.isversionof10.1186/1471-2334-12-42en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.titleComparative activity of carbapenem testing (the COMPACT study) in Turkeyen_US
dc.typearticleen_US
dc.contributor.departmentOMÜen_US
dc.identifier.volume12en_US
dc.relation.journalBmc Infectious Diseasesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster